Pfizer's Oncology Breakthrough: Combination Therapy Shows Unprecedented Efficacy in Bladder Cancer

Phase 3 trial data shows PADCEV+Keytruda combo cuts recurrence risk by 47% vs chemo in muscle-invasive bladder cancer, doubling complete response rates.

New clinical trial results from Pfizer and its development partners Astellas and Merck have delivered what analysts are calling a potential paradigm shift in the treatment of a specific form of bladder cancer. The data, presented on February 27, 2026, at the ASCO GU Symposium, demonstrate a striking advantage for a novel drug combination over the current standard of care.

A New Standard of Care on the Horizon

The Phase 3 trial, known as EV-304/KEYNOTE-B15, evaluated a treatment regimen combining PADCEV (enfortumab vedotin) and Keytruda (pembrolizumab) in patients diagnosed with cisplatin-eligible muscle-invasive bladder cancer. The findings indicate a profound improvement in patient outcomes, positioning the combination as a likely candidate for regulatory approval and subsequent adoption as a first-line therapy.

The most compelling statistic is a 47% reduction in the risk of disease recurrence, progression, or death compared to the traditional chemotherapy combination of gemcitabine and cisplatin. This superior efficacy was consistent across all key endpoints studied.

Survival and Response Rates Redefined

After a median follow-up period of 33.6 months, researchers had not yet reached the median event-free survival time for patients receiving the PADCEV-Keytruda combination. In stark contrast, the median event-free survival for the standard chemotherapy group was 48.5 months. The two-year event-free survival rate told a similar story: 79.4% for the novel therapy versus 66.2% for standard treatment.

Perhaps the most dramatic result was the rate of complete pathological response—a state where no detectable cancer remains after treatment. Over half (55.8%) of the patients on the combination therapy achieved this milestone, nearly doubling the 32.5% rate observed in the control group. Furthermore, the overall risk of death was lowered by 35% for those receiving the investigational treatment.

Regulatory Pathway and Market Impact

In response to these robust results, Pfizer, Astellas, and Merck have announced plans to promptly submit applications for regulatory approval with health authorities worldwide. The clear and consistent data superiority across all measured outcomes significantly increases the likelihood of a favorable review.

If approved, this drug combination is poised to become the new foundational treatment for this patient population, fundamentally altering the clinical management of muscle-invasive bladder cancer and representing a significant advancement in oncology care.